 |
|
|
REFERENCES
151.
Murray M: Induction and inhibition of CYPs and
implications for medicine. Mol Aspects Med 20(1–2):24–33, 34–137,
1999.
152.
Hasle JA: Pharmacogenetics of cytochromes P450.
Mol Aspects Med 20(1–2):12–24, 25–137, 1999.
153.
Sies H: Oxidative stress: from basic research
to clinical application. Am J Med 91(3C):31S–38S, 1991.
154.
Conney AH: Pharmacological implications of microsomal
enzyme induction. Pharmacol Rev 19(3):317–366, 1967.
155.
Sesardic D, Boobis AR, Edwards RJ, et al: A form
of cytochrome P450 in man, orthologous to formed in the rat, catalyses the O-deethylation
of phenacetin and is inducible by cigarette smoking. Br J Clin Pharmacol 26(4):363–372,
1988.
156.
Moore LB, Goodwin B, Jones SA, et al: St. John's
wort induces hepatic drug metabolism through activation of the pregnane X receptor.
Proc Natl Acad Sci U S A 97(13):7500–7502, 2000.
157.
Sinclair JF, Szakacs JG, Wood SG, et al: Acetaminophen
hepatotoxicity precipitated by short-term treatment of rats with ethanol and isopentanol:
Protection by triacetyloleandomycin. Biochem Pharmacol 59(4):445–454, 2000.
158.
Goodwin B, Hodgson E, Liddle C: The orphan human
pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin
through a distal enhancer module. Mol Pharmacol 56(6):1329–1339, 1999.
159.
Moore LB, Parks DJ, Jones SA, et al: Orphan nuclear
receptors constitutive androstane receptor and pregnane X receptor share xenobiotic
and steroid ligands. J Biol Chem 275(20):15122–15127, 2000.
160.
del Castillo-Olivares A, Gil G: Role of FXR and
FTF in bile acid-mediated suppression of cholesterol 7 alpha-hydroxylase transcription.
Nucleic Acids Res 28(18):3587–3593, 2000.
161.
Meech R, Mackenzie PI: Structure and function
of uridine diphosphate glucuronosyltransferases. Clin Exp Pharmacol Physiol 24(12):907–915,
1997.
162.
Lee J, Boyer JL: Molecular alterations in hepatocyte
transport mechanisms in acquired cholestatic liver disorders. Semin Liver Dis 20(3):373–384,
2000.
163.
Trauner M, Meier PJ, Boyer JL: Molecular pathogenesis
of cholestasis. N Engl J Med 339(17):1217–1227, 1998.
164.
Huang L, Smith JW, Meijer DK, et al: Mrp2 is
essential for estradiol-17beta(beta-D-glucuronide)-induced cholestasis in rats.
Hepatology 32(1):66–72, 2000.
165.
Stieger B, Fattinger K, Madon J, et al: Drug-
and estrogen-induced cholestasis through inhibition of the hepatocellular bile salt
export pump (Bsep) of rat liver. Gastroenterology 118(2):422–430, 2000.
166.
George J, Byth K, Farrell GC: Influence of clinicopathological
variables on CYP protein expression in human liver. J Gastroenterol Hepatol 11(1):33–39,
1996.
167.
Alvares AP, Anderson KE, Conney AH, et al: Interactions
between nutritional factors and drug biotransformations in man. Proc Natl Acad Sci
U S A 73(7):2501–2504, 1976.
168.
Pantuck EJ, Pantuck CB, Weissman C, et al: Effects
of parenteral nutritional regimens on oxidative drug metabolism. Anesthesiology
60(6):534–536, 1984.
169.
Whitehouse MW, Beck FJ: Impaired drug metabolism
in rats with adjuvant-induced arthritis: A brief review. Drug Metab Dispos 1(1):251–255,
1973.
170.
Elin RJ, Vesell ES, Wolff SM: Effects of etiocholanolone-induced
fever on plasma antipyrine half-lives and metabolic clearance. Clin Pharmacol Ther
17(4):447–457, 1975.
171.
George J, Byth K, Farrell GC: Age but not gender
selectively affects expression of individual cytochrome P450 proteins in human liver.
Biochem Pharmacol 50(5):727–730, 1995.
172.
Turnheim K: Drug dosage in the elderly. Is it
rational? Drugs Aging 13(5):357–379, 1998.
173.
Hammerlein A, Derendorf H, Lowenthal DT: Pharmacokinetic
and pharmacodynamic changes in the elderly. Clinical implications. Clin Pharmacokinet
35(1):49–64, 1998.
174.
Dodds C: Anaesthetic drugs in the elderly. Pharmacol
Ther 66(2):369–386, 1995.
175.
Reilly CS, Wood AJ, Koshakji RP, et al: The effect
of halothane on drug disposition: contribution of changes in intrinsic drug metabolizing
capacity and hepatic blood flow. Anesthesiology 63(1):70–76, 1985.
176.
Aune H, Bessesen A, Olsen H, et al: Acute effects
of halothane and enflurane on drug metabolism and protein synthesis in isolated rat
hepatocytes. Acta Pharmacol Toxicol (Copenh) 53(5):363–368, 1983.
177.
Livingston A, Waterman AE: The development of
tolerance to ketamine in rats and the significance of hepatic metabolism. Br J Pharmacol
64(1):63–69, 1978.
178.
Kanto J, Iisalo E, Lehtinen V, et al: The concentrations
of diazepam and its metabolites in the plasma after an acute and chronic administration.
Psychopharmacologia 36(2):123–131, 1974.
179.
Karlin JM, Kutt H: Acute diphenylhydantoin intoxication
following halothane anesthesia. J Pediatr 76(6):941–944, 1970.
180.
Ghoneim MM, Delle M, Wilson WR, et al: Alteration
of warfarin kinetics in man associated with exposure to an operating-room environment.
Anesthesiology 43(3):333–336, 1975.
181.
White PF, Johnston RR, Pudwill CR: Interaction
of ketamine and halothane in rats. Anesthesiology 42(2):179–186, 1975.
182.
Fish KJ, Rice SA: Halothane inhibits metabolism
of enflurane in Fischer 344 rats. Anesthesiology 59(5):417–420, 1983.
183.
Dale O, Nielsen K, Westgaard G, et al: Drug metabolizing
enzymes in the rat after inhalation of halothane and enflurane. Different pattern
of response in liver, kidney and lung and possible implications for toxicity. Br
J Anaesth 55(12):1217–1224, 1983.
184.
Duvaldestin P, Mazze RI, Nivoche Y, et al: Occupational
exposure to halothane results in enzyme induction in anesthetists. Anesthesiology
54(1):57–60, 1981.
185.
Wilkinson GR, Schenker S: Drug disposition and
liver disease. Drug Metab Rev 4(2):139–175, 1975.
186.
Wilkinson GR, Shand DG: Commentary: A physiological
approach to hepatic drug clearance. Clin Pharmacol Ther 18(4):377–390, 1975.
187.
Williams RL, Mamelok RD: Hepatic disease and
drug pharmacokinetics. Clin Pharmacokinet 5(6):528–547, 1980.
188.
Williams RL: Drug administration in hepatic disease.
N Engl J Med 309(26):1616–1622, 1983.
189.
Adedoyin A, Branch RA: Pharmacokinetics. In
Zakim D, Boyer TD (eds): Hepatology: A Textbook of Liver Disease, 3rd ed. Philadelphia,
WB Saunders, 1996, pp 307–322.
190.
Davern TJ, Scharschmidt BF: Biochemical liver
tests. In Feldman M, Friedman LS, Sleisenger, MH
(eds): Sleisenger & Fordtran's Gastrointestinal and Liver Disease: Pathophysiology/Diagnosis/Management,
7th ed. St. Louis, WB Saunders, 2002, pp 1227–1239.
191.
Hussey AJ, Aldridge LM, Paul D, et al: Plasma
glutathione S-transferase concentration as a measure of hepatocellular integrity
following a single general anaesthetic with halothane, enflurane or isoflurane.
Br J Anaesth 60(2):130–135, 1988.
192.
Redick JA, Jakoby WB, Baron J: Immunohistochemical
localization of glutathione S-transferases in livers of untreated rats. J Biol Chem
257(24):15200–15203, 1982.
193.
Rothschild MA, Oratz M, Zimmon D, et al: Albumin
synthesis in cirrhotic subjects with ascites studied with carbonate-14C. J Clin
Invest 48(2):344–350, 1969.
194.
Sussman NL: Fulminant hepatic failure. In
Zakim D, Boyer TD (eds): Hepatology: A Textbook of Liver Disease, 3rd ed. Philadelphia,
WB. Saunders, 1996, pp 618–650.
195.
Aranha GV, Greenlee HB: Intra-abdominal surgery
in patients with advanced cirrhosis. Arch Surg 121(3):275–277, 1986.
196.
Roy-Chowdhury J, Jansen PLM: Bilirubin metabolism
and its disorders. In Zakim D, Boyer TD (eds):
Hepatology: A Textbook of Liver Disease, 3rd ed. Philadelphia, WB Saunders, 1996,
pp 323–362.
197.
Drygiannakis D, Lionis C, Drygiannakis I, et al:
Low prevalence of liver-kidney microsomal autoantibodies of type 1 (LKM1) in hepatitis
C seropositive subjects on Crete, Greece. BMC Gastroenterol 1(1):4, 2001.
198.
Zamanou A, Tsirogianni A, Terzoglou C, et al:
Anti-smooth muscle antibodies (ASMAs) and anti-cytoskeleton antibodies (ACTAs) in
liver diseases: A comparison of classical indirect immunofluorescence with ELISA.
J Clin Lab Anal 16(4):194–201, 2002.
199.
Strassburg CP, Manns MP: Autoimmune tests in
primary biliary cirrhosis. Baillieres Best Pract Res Clin Gastroenterol 14(4):585–599,
2000.
200.
Nocente R, Ceccanti M, Bertazzoni G, et al: HCV
infection and extrahepatic manifestations. Hepatogastroenterology 50(52):1149–1154,
2003.
201.
Invernizzi P, Crosignani A, Battezzati PM, et
al: Comparison of the clinical features and clinical course of antimitochon-drial
antibody-positive and -negative primary biliary cirrhosis. Hepatology 25(5):1090–1095,
1997.
202.
Long SA, Van de Water J, Gershwin ME: Antimitochondrial
antibodies in primary biliary cirrhosis: The role of xenobiotics. Autoimmun Rev
1(1–2):37–42, 2002.
203.
Jones DE: Autoantigens in primary biliary cirrhosis.
J Clin Pathol 53(11):813–821, 2000.
204.
Mondelli MU, Manns M Ferrari, C: Does the immune
response play a role in the pathogenesis of chronic liver disease? Arch Pathol Lab
Med 112(5):489–497, 1988.
205.
Nishio A, Bass NM, Luketic VA, et al: Primary
biliary cirrhosis: from induction to destruction. Semin Gastrointest Dis 12(2):89–102,
2001.
206.
Sasaki M, Ansari AA, Nakanuma Y, et al: The immunopathology
of primary biliary cirrhosis: thoughts for the millennium. Arch Immunol Ther Exp
(Warsz) 48(1):1–10, 2000.
207.
Okolicsanyi L, Fabris L: Diagnostic approach
to primary sclerosing cholangitis: open questions. Ital J Gastroenterol 23(7):436–441,
1991.
208.
Tanaka A, Miyakawa H, Luketic, VA et al: The
diagnostic value of anti-mitochondrial antibodies, especially in primary biliary
cirrhosis. Cell Mol Biol (Noisy-le-grand) 48(3):295–299, 2002.
209.
Lacerda MA, Ludwig J, Dickson ER, et al: Antimitochondrial
antibody-negative primary biliary cirrhosis. Am J Gastroenterol 90(2):247–249,
1995.
210.
Czaja A: Autoimmune liver disease. In
Zakim D, Boyer T (eds): Hepatology: A Textbook of Liver Disease, 3rd ed. Philadelphia,
WB Saunders, 1996, pp 1259–1292.
211.
Czaja AJ: Autoimmune hepatitis. In
Feldman M, Friedman LS, Sleisenger MH (eds): Sleisenger & Fordtran's Gastrointestinal
and Liver Disease: Pathophysiology/Diagnosis/Management, 7th ed. St. Louis, WB
Saunders, 2002, pp 1462–1474.
212.
Ajisaka H, Shimizu K, Miwa K: Immunohistochemical
study of protein induced by vitamin K absence or antagonist II in hepatocellular
carcinoma. J Surg Oncol 84(2):89–93, 2003.
213.
Sugimoto H, Takeda S, Inoue S, et al: Des-gamma-carboxy
prothrombin (DCP) ratio, a novel parameter measured by monoclonal antibodies MU-3
and 19B7, as a new prognostic indicator for hepatocellular carcinoma. Liver Int
23(1):38–44, 2003.
214.
Yamanaka J, Yamanaka N, Nakasho K, et al: Clinicopathologic
analysis of stage II-III hepatocellular carcinoma showing early massive recurrence
after liver resection. J Gastroenterol Hepatol 15(10):1192–1198, 2000.
215.
Fujioka M, Nakashima Y, Nakashima O, et al: Immunohistologic
study on the expressions of alpha-fetoprotein and protein induced by vitamin K absence
or antagonist II in surgically resected small hepatocellular carcinoma. Hepatology
34(6):1128–1134, 2001.
216.
Cui R, He J, Zhang F, et al: Diagnostic value
of protein induced by vitamin K absence (PIVKAII) and hepatoma-specific band of serum
gamma-glutamyl transferase (GGTII) as hepatocellular carcinoma markers complementary
to alpha-fetoprotein. Br J Cancer 88(12):1878–1882, 2003.
217.
Barnes P, Lunzer M, O'Halloran M: Comparative
sensitivity of serum cholylglycine concentration and bromsulphalein retention in
patients with early and late alcoholic liver disease. Aust N Z J Med 16(6):785–787,
1986.
218.
Denaro CP, Jacob P 3rd, Benowitz NL: Evaluation
of pharmacokinetic methods used to estimate caffeine clearance and comparison with
a Bayesian forecasting method. Ther Drug Monit 20(1):78–87, 1998.
219.
Jover R, Carnicer F, Sanchez-Paya J, et al: Salivary
caffeine clearance predicts survival in patients with liver cirrhosis. Am J Gastroenterol
92(10):1905–1908, 1997.
220.
Lewis FW, Rector WG JR: Caffeine clearance in
cirrhosis. The value of simplified determinations of liver metabolic capacity [comment].
J Hepatol 14(2–3):157–162, 1992.
221.
McDonagh JE, Nathan VV, Bonavia IC, et al: Caffeine
clearance by enzyme multiplied immunoassay technique: A simple, inexpensive, and
useful indicator of liver function. Gut 32(6):681–684, 1991.
222.
Wahllander A, Mohr S, Paumgartner, G: Assessment
of hepatic function. Comparison of caffeine clearance in serum and saliva during
the day and at night. J Hepatol 10(2):129–137, 1990.
223.
Schnegg M, Lauterburg BH: Quantitative liver
function in the elderly assessed by galactose elimination capacity, aminopyrine demethylation
and caffeine clearance. J Hepatol 3(2):164–171, 1986.
224.
Szabo G, Benyo I, Sandor J, et al: Estimation
of the hepatic blood flow in the dog with the Xe133 and hydrogen wash-out Au190-colloid
uptake techniques and with the electromagnetic flowmeter. Res Exp Med (Berl) 169(1):69–76,
1976.
225.
Kraul H, Truckenbrodt J, Sigusch H, et al: [Comparison
of ICG elimination with biotransformation of model substances and histological features
of liver biopsy in liver diseases]. Gastroenterol J 51(3–4):123–128,
1991.
226.
Huet PM, Lavoie P, Viallet A: Simultaneous estimation
of hepatic and portal blood flows by an indicator dilution technique. J Lab Clin
Med 82(5):836–846, 1973.
227.
Hopkinson BR, Schenk WG JR: The electromagnetic
measurement of liver blood flow and cardiac output in conscious dogs during feeding
and exercise. Surgery 63(6):970–975, 1968.
228.
Whitcomb DC: Hereditary and childhood disorders
of the pancreas, including cystic fibrosis. In Feldman
M, Friedman LS, Sleisenger MH (eds): Sleisenger & Fordtran's Gastrointestinal
and Liver Disease: Pathophysiology/Diagnosis/Management, 7th ed. St. Louis, WB
Saunders, 2002, pp 881–912.
229.
Kang HK, Jeong YY, Choi JH, et al: Three-dimensional
multi-detector row CT portal venography in the evaluation of portosystemic collateral
vessels in liver cirrhosis. Radiographics 22(5):1053–1061, 2002.
230.
Ostroff JW, LaBerge JM: Endoscopic and radiologic
treatment of biliary disease. In Feldman M, Friedman
LS, Sleisenger MH (eds): Sleisenger & Fordtran's Gastrointestinal and Liver
Disease: Pathophysiology/Diagnosis/Management, 7th ed. St. Louis, WB Saunders,
2002, pp 1167–1192.
231.
Toledo-Pereyra LH, Suzuki S: Cellular and biomolecular
mechanisms of liver ischemia and reperfusion injury. Transplant Proc 26(1):325–327,
1994.
232.
Kurokawa T, Nonami T, Harada A, et al: Mechanism
and prevention of ischemia-reperfusion injury of the liver. Semin Surg Oncol 12(3):179–182,
1996.
233.
Kaplowitz N: Mechanisms of liver cell injury.
J Hepatol 32(1 Suppl):39–47, 2000.
234.
Galle PR: Apoptosis in liver disease. J Hepatol
27(2):405–412, 1997.
235.
Patel T, Steer CJ, Gores GJ: Apoptosis and the
liver: A mechanism of disease, growth regulation, and carcinogenesis. Hepatology
30(3):811–815, 1999.
236.
Patel T: Apoptosis in hepatic pathophysiology.
Clin Liver Dis 4(2):295–317, 2000.
237.
Kaplowitz N: Cell death at the millennium. Implications
for liver diseases. Clin Liver Dis 4(1):1–23, v, 2000.
238.
Nielsen VG, McCammon AT, Tan S, et al: Xanthine
oxidase inactivation attenuates postocclusion shock after descending thoracic aorta
occlusion and reperfusion in rabbit. J Thorac Cardiovasc Surg 110(3):715–722,
1995.
239.
Jaeschke H, Gores GJ, Cederbaum AI, et al: Mechanisms
of hepatotoxicity. Toxicol Sci 65(2):166–176, 2002.
240.
Carden DL, Granger DN: Pathophysiology of ischaemia-reperfusion
injury. J Pathol 190(3):255–266, 2000.
241.
Arai M, Thurman RG, Lemasters JJ: Ischemic preconditioning
of rat livers against cold storage-reperfusion injury: Role of nonparenchymal cells
and the phenomenon of heterologous preconditioning [comment]. Liver Transpl 7(4):292–299,
2001.
242.
Weinbroum A, Nielsen VG, Tan S, et al: Liver
ischemia-reperfusion increases pulmonary permeability in rat: Role of circulating
xanthine oxidase. Am J Physiol 268(6 Pt 1):G988–996, 1995.
243.
Kaplowitz N, Tsukamoto H: Oxidative stress and
liver disease. Prog Liver Dis 14:131–159, 1996.
244.
Ursini F, Maiorino M, Roveri A: Phospholipid
hydroperoxide glutathione peroxidase (PHGPx): More than an antioxidant enzyme?
Biomed Environ Sci 10(2–3):327–332, 1997.
245.
Doroshow JH, Akman S, Chu FF, et al: Role of
the glutathione-glutathione peroxidase cycle in the cytotoxicity of the anticancer
quinones. Pharmacol Ther 47(3):359–370, 1990.
246.
Michiels C, Raes M, Toussain O, et al: Importance
of Se-glutathione peroxidase, catalase, and Cu/Zn-SOD for cell survival against oxidative
stress. Free Radic Biol Med 17(3):235–248, 1994.
247.
Luo GM, Ren XJ, Liu JQ, et al: Towards more efficient
glutathione peroxidase mimics: substrate recognition and catalytic group assembly.
Curr Med Chem 10(13):1151–1183, 2003.
248.
Kim JS, Qian T, Lemasters JJ: Mitochondrial permeability
transition in the switch from necrotic to apoptotic cell death in ischemic rat hepatocytes.
Gastroenterology 124(2):494–503, 2003.
249.
Sawaya DE Jr, Brown M, Minardi A, et al: The
role of ischemic preconditioning in the recruitment of rolling and adherent leukocytes
in hepatic venules after ischemia/reperfusion. J Surg Res 85(1):163–170, 1999.
250.
Kurose I, Argenbright LW, Wolf R, et al: Ischemia/reperfusion-induced
microvascular dysfunction: role of oxidants and lipid mediators. Am J Physiol 272(6
Pt 2):H2976–2982, 1997.
251.
Yokoyama Y, Beckman JS, Beckman TK, et al: Circulating
xanthine oxidase: potential mediator of ischemic injury. Am J Physiol 258(4 Pt
1):G564–570, 1990.
252.
Adkison D, Hollwarth ME, Benoit JN, et al: Role
of free radicals in ischemia-reperfusion injury to the liver, Acta Physiol Scand
Suppl 548:101–107, 1986.
253.
Toledo-Pereyra LH: Liver preservation: experimental
and clinical observations. Transplant Proc 20(5):965–968, 1988.
254.
Nielsen VG, Tan S, Weinbroum A, et al: Lung injury
after hepatoenteric ischemia-reperfusion: Role of xanthine oxidase. Am J Respir
Crit Care Med 154(5):1364–1369, 1996.
255.
Nielsen VG, Tan S, Baird MS, et al: Gastric intramucosal
pH and multiple organ injury: impact of ischemia-reperfusion and xanthine oxidase.
Crit Care Med 24(8):1339–1344, 1996.
256.
Nielsen VG, Tan S, Baird MS, et al: Xanthine
oxidase mediates myocardial injury after hepatoenteric ischemia-reperfusion. Crit
Care Med 25(6):1044–1050, 1997.
257.
Nielsen VG, Tan S, Kirk KA, et al: Halothane
and xanthine oxidase increase hepatocellular enzyme release and circulating lactate
after ischemia-reperfusion in rabbits. Anesthesiology 87(4):908–917, 1997.
258.
Nielsen VG, Tan S, Brix AE, et al: Hextend (hetastarch
solution) decreases multiple organ injury and xanthine oxidase release after hepatoenteric
ischemia-reperfusion in rabbits. Crit Care Med 25(9):1565–1574, 1997.
259.
Pesonen EJ, Linder N, Raivio KO, et al: Circulating
xanthine oxidase and neutrophil activation during human liver transplantation. Gastroenterology
114(5):1009–1015, 1998.
260.
Tan S, Yokoyama Y, Dickens E, et al: Xanthine
oxidase activity in the circulation of rats following hemorrhagic shock. Free Radic
Biol Med 15(4):407–414, 1993.
261.
Radi R, Rubbo H, Bush K, et al: Xanthine oxidase
binding to glycosaminoglycans: Kinetics and superoxide dismutase interactions of
immobilized xanthine oxidase-heparin complexes. Arch Biochem Biophys 339(1):125–135,
1997.
262.
Adachi T, Fukushima T, Usami Y, et al: Binding
of human xanthine oxidase to sulphated glycosaminoglycans on the endothelial-cell
surface. Biochem J 289(Pt 2):523–527, 1993.
263.
Beckman JS, Koppenol WH: Nitric oxide, superoxide,
and peroxynitrite: The good, the bad, and ugly. Am J Physiol 271(5 Pt 1):C1424–1437,
1996.
264.
Jamieson NV, Sundberg R, Lindell S, et al: The
24- to 48-hour preservation of canine liver by simple cold storage using UW lactobionate
solution. Transplant Proc 21(1 Pt 2):1292–1293, 1989.
265.
Marsh DC, Vreugdenhil PK, Mack VE, et al: Glycine
protects hepatocytes from injury caused by anoxia, cold ischemia and mitochondrial
inhibitors, but not injury caused by calcium ionophores or oxidative stress. Hepatology
17(1):91–98, 1993.
266.
den Butter G, Marsh DC, Lindell SL, et al: Amino
acids to suppress reperfusion injury after liver preservation. Transplant Proc 23(5):2378–2379,
1991.
267.
Jaeschke H, Lemasters JJ: Apoptosis versus oncotic
necrosis in hepatic ischemia/reperfusion injury. Gastroenterology 125(4):1246–1257,
2003.
268.
Sindram D, Rudiger, HA, Upadhya AG, et al: Ischemic
preconditioning protects against cold ischemic injury through an oxidative stress
dependent mechanism. J Hepatol 36(1):78–84, 2002.
269.
Lehnert M, Artee GE, Smutney OM, et al: Dependence
of liver injury after hemorrhage/resuscitation in mice on NADPH oxidase-derived superoxide.
Shock 19(4):345–351, 2003.
270.
Schemmer P, Connor HD, Arteel GE, et al: Reperfusion
injury in livers due to gentle in situ organ manipulation during harvest involves
hypoxia and free radicals. J Pharmacol Exp Ther 290(1):235–240, 1999.
271.
Lee YG, Lee SH, Lee SM: Role of Kupffer cells
in cold/warm ischemia-reperfusion injury of rat liver. Arch Pharm Res 23(6):620–625,
2000.
272.
Schauer RJ, Bilzer M, Kalmuk S, et al: Microcirculatory
failure after rat liver transplantation is related to Kupffer cell-derived oxidant
stress but not involved in early graft dysfunction. Transplantation 72(10):1692–1699,
2001.
273.
Radi R, Cassina A, Hodara R: Nitric oxide and
peroxynitrite interactions with mitochondria. Biol Chem 383(3–4):401–409,
2002.
274.
Warle MC, Farhan A, Metselaar HJ, et al: In vitro
cytokine production of TNFalpha and IL-13 correlates with acute liver transplant
rejection. Hum Immunol 62(11):1258–1265, 2001.
275.
Imamura H, Sutto F, Brault A, et al: Role of
Kupffer cells in cold ischemia/reperfusion injury of rat liver [comment]. Gastroenterology
109(1):189–197, 1995.
276.
Kerkweg U, Jacob M, De Groot H, et al: Cold-induced
apoptosis of rat liver endothelial cells: contribution of mitochondrial alterations.
Transplantation 76(3):501–508, 2003.
277.
Doeppner TR, Grune T, de Groot H, et al: Cold-induced
apoptosis of rat liver endothelial cells: involvement of the proteasome. Transplantation
75(12):1946–1953, 2003.
278.
Sindram D, Porte RJ, Hoffman MR, et al: Platelets
induce sinusoidal endothelial cell apoptosis upon reperfusion of the cold ischemic
rat liver. Gastroenterology 118(1):183–191, 2000.
279.
Lemasters JJ, Thurman RG: Reperfusion injury
after liver preservation for transplantation. Annu Rev Pharmacol Toxicol 37:327–338,
1997.
280.
Shedlofsky SI, Israel BC, McClain CJ, et al:
Endotoxin administration to humans inhibits hepatic cytochrome P450-mediated drug
metabolism. J Clin Invest 94(6):2209–2214, 1994.
281.
Gerson RJ, Casini A, Gilfor D, et al: Oxygen-mediated
cell injury in the killing of cultured hepatocytes by acetaminophen. Biochem Biophys
Res Commun 126(3):1129–1137, 1985.
282.
Casini A, Giorli M, Hyland RJ, et al: Mechanisms
of cell injury in the killing of cultured hepatocytes by bromobenzene. J Biol Chem
257(12):6721–6728, 1982.
283.
Tang W, Stearns RA, Bandiera SM, et al: Studies
on cytochrome P-450-mediated bioactivation of diclofenac in rats and in human hepatocytes:
Identification of glutathione conjugated metabolites. Drug Metab Dispos 27(3):365–372,
1999.
284.
Wang M, Dickinson RG: Disposition and covalent
binding of diflunisal and diflunisal acyl glucuronide in the isolated perfused rat
liver. Drug Metab Dispos 26(2):98–104, 1998.
285.
Tang W, Borel AG, Abbott FS: Conjugation of glutathione
with a toxic metabolite of valproic acid, (E)-2-propyl-2,4-pentadienoic acid, catalyzed
by rat hepatic glutathione-S-transferases. Drug Metab Dispos 24(4):436–446,
1996.
286.
Fau D, Lekehal M, Farrell G, et al: Diterpenoids
from germander, an herbal medicine, induce apoptosis in isolated rat hepatocytes
[comment]. Gastroenterology 113(4):1334–1346, 1997.
287.
Haouzi D, Lekehal M, Moreau A, et al: Cytochrome
P450-generated reactive metabolites cause mitochondrial permeability transition,
caspase activation, and apoptosis in rat hepatocytes. Hepatology 32(2):303–311,
2000.
288.
Lewis W, Dalakas MC: Mitochondrial toxicity of
antiviral drugs. Nat Med 1(5):417–422, 1995.
289.
Gut J, Christen U, Huwyler J, et al: Molecular
mimicry of trifluoroacetylated human liver protein adducts by constitutive proteins
and immunochemical evidence for its impairment in halothane hepatitis. European
Journal of Biochemistry 210(2):569–576, 1992.
290.
Kretz-Rommel A, Boelsterli UA: Cytotoxic activity
of T cells and non-T cells from diclofenac-immunized mice against cultured syngeneic
hepatocytes exposed to diclofenac. Hepatology 22(1):213–222, 1995.
291.
Bourdi M, Larrey D, Nataf J, et al: Anti-liver
endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2.
A specific marker of dihydralazine-induced hepatitis. J Clin Invest 85(6):1967–1973,
1990.
292.
Lecoeur S, Bonierbale E, Challine D, et al: Specificity
of in vitro covalent binding of tienilic acid metabolites to human liver microsomes
in relationship to the type of hepatotoxicity: comparison with two directly hepatotoxic
drugs. Chem Res Toxicol 7(3):434–442, 1994.
293.
Mushlin PS, Gelman S: Liver dysfunction after
anesthesia. In Benumof JL, Saidman LJ (eds): Anesthesia
and Perioperative Complications, 2nd ed. St. Louis, Mosby, 1999, pp 441–470.
294.
Bardag-Gorce F, French BA, Li J, et al: The importance
of cycling of blood alcohol levels in the pathogenesis of experimental alcoholic
liver disease in rats. Gastroenterology 123(1):325–335, 2002.
295.
Tonnesen H, Kehlet H: Preoperative alcoholism
and postoperative morbidity. Br J Surg 86(7):869–874, 1999.
296.
Nanji AA, Su GL, Laposata M, et al: Pathogenesis
of alcoholic liver disease—recent advances. Alcohol Clin Exp Res 26(5):731–736,
2002.
297.
Lieber CS: S-adenosyl-L-methionine: Its role
in the treatment of liver disorders. Am J Clin Nutr 76(5):1183S–1187S, 2002.
298.
Lieber CS: Alcoholic liver injury: Pathogenesis
and therapy in 2001. Pathol Biol 49(9):738–752, 2001.
299.
Lieber CS: Alcoholic liver disease: New insights
in pathogenesis lead to new treatments. J Hepatol 32(1 Suppl):113–128, 2000.
300.
Lieber CS: Microsomal ethanol-oxidizing system
(MEOS): The first 30 years (1968–1998)—a review. Alcohol Clin Exp Res
23(6):991–1007, 1999.
